File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: Combination therapy and adiponectin

TitleImpact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: Combination therapy and adiponectin
Authors
Issue Date2011
PublisherJTE Multimedia, LLC. The Journal's web site is located at http://www.postgradmed.com/
Citation
Postgraduate Medicine, 2011, v. 123 n. 6, p. 66-71 How to Cite?
AbstractBackground: In many countries, combination therapy with amlodipine and atorvastatin is indicated for the treatment of patients with hypertension and hypercholesterolemia. The aim of this study was to investigate the impact of this combination therapy on plasma adiponectin levels. Hypothesis: Combination therapy with amlodipine and atorvastatin would increase plasma adiponectin levels. Methods: A total of 25 patients with coronary artery disease and concomitant hypertension and hypercholesterolemia were evaluated. The combination of amlodipine and atorvastatin in 8 different dosage strengths were flexibly titrated over a period of 14 weeks. Lipid profile and plasma adiponectin were measured. Brachial flow-mediated dilation (FMD) was determined by vascular ultrasound. Results: As compared with baseline, combination therapy with amlodipine and atorvastatin signifi cantly reduced systolic and diastolic blood pressure, total cholesterol, and low-density lipoprotein cholesterol (all P < 0.05). Furthermore, there were signifi cant increases in adiponectin levels (mean [95% confidence interval (CI)], 12.1 [10.7-13.7] vs 8.1 [6.5-10.0] μg/mL; P < 0.001) and brachial FMD (4.4 ± 0.6% vs 5.6 ± 0.5%; P = 0.046) over 14 weeks of treatment. The change in adiponectin levels correlated significantly with the changes in diastolic blood pressure (r = -0.49; P = 0.014) and FMD (r = 0.55; P = 0.007). Conclusion: The results of this study indicate that along with its antihypertensive and cholesterol-lowering effects, combination therapy with amlodipine and atorvastatin appears to increase plasma adiponectin levels and improve endothelial function. © Postgraduate Medicine.
Persistent Identifierhttp://hdl.handle.net/10722/163423
ISSN
2015 Impact Factor: 1.906
2015 SCImago Journal Rankings: 0.599
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLi, Men_US
dc.contributor.authorXu, Aen_US
dc.contributor.authorLam, KSLen_US
dc.contributor.authorCheung, BMYen_US
dc.contributor.authorTse, HFen_US
dc.date.accessioned2012-09-05T05:31:12Z-
dc.date.available2012-09-05T05:31:12Z-
dc.date.issued2011en_US
dc.identifier.citationPostgraduate Medicine, 2011, v. 123 n. 6, p. 66-71en_US
dc.identifier.issn0032-5481en_US
dc.identifier.urihttp://hdl.handle.net/10722/163423-
dc.description.abstractBackground: In many countries, combination therapy with amlodipine and atorvastatin is indicated for the treatment of patients with hypertension and hypercholesterolemia. The aim of this study was to investigate the impact of this combination therapy on plasma adiponectin levels. Hypothesis: Combination therapy with amlodipine and atorvastatin would increase plasma adiponectin levels. Methods: A total of 25 patients with coronary artery disease and concomitant hypertension and hypercholesterolemia were evaluated. The combination of amlodipine and atorvastatin in 8 different dosage strengths were flexibly titrated over a period of 14 weeks. Lipid profile and plasma adiponectin were measured. Brachial flow-mediated dilation (FMD) was determined by vascular ultrasound. Results: As compared with baseline, combination therapy with amlodipine and atorvastatin signifi cantly reduced systolic and diastolic blood pressure, total cholesterol, and low-density lipoprotein cholesterol (all P < 0.05). Furthermore, there were signifi cant increases in adiponectin levels (mean [95% confidence interval (CI)], 12.1 [10.7-13.7] vs 8.1 [6.5-10.0] μg/mL; P < 0.001) and brachial FMD (4.4 ± 0.6% vs 5.6 ± 0.5%; P = 0.046) over 14 weeks of treatment. The change in adiponectin levels correlated significantly with the changes in diastolic blood pressure (r = -0.49; P = 0.014) and FMD (r = 0.55; P = 0.007). Conclusion: The results of this study indicate that along with its antihypertensive and cholesterol-lowering effects, combination therapy with amlodipine and atorvastatin appears to increase plasma adiponectin levels and improve endothelial function. © Postgraduate Medicine.en_US
dc.languageengen_US
dc.publisherJTE Multimedia, LLC. The Journal's web site is located at http://www.postgradmed.com/-
dc.relation.ispartofPostgraduate Medicineen_US
dc.subject.meshAdiponectin - Blooden_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAmlodipine - Pharmacology - Therapeutic Useen_US
dc.subject.meshAnticholesteremic Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshAntihypertensive Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshBiological Markers - Blooden_US
dc.subject.meshBlood Pressure - Drug Effectsen_US
dc.subject.meshBrachial Artery - Physiology - Ultrasonographyen_US
dc.subject.meshCholesterol - Blooden_US
dc.subject.meshCoronary Artery Disease - Blood - Complications - Drug Therapyen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDrug Combinationsen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshEndothelium, Vascular - Drug Effects - Physiologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHeptanoic Acids - Pharmacology - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshHypertension - Blood - Complications - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPyrroles - Pharmacology - Therapeutic Useen_US
dc.subject.meshTriglycerides - Blooden_US
dc.titleImpact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: Combination therapy and adiponectinen_US
dc.typeArticleen_US
dc.identifier.emailXu, A:amxu@hkucc.hku.hken_US
dc.identifier.emailLam, KSL:ksllam@hku.hken_US
dc.identifier.emailCheung, BMY:mycheung@hku.hken_US
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_US
dc.identifier.authorityXu, A=rp00485en_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.identifier.authorityCheung, BMY=rp01321en_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.3810/pgm.2011.11.2496en_US
dc.identifier.pmid22104455-
dc.identifier.scopuseid_2-s2.0-82155192798en_US
dc.identifier.hkuros205185-
dc.identifier.hkuros213327-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-82155192798&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume123en_US
dc.identifier.issue6en_US
dc.identifier.spage66en_US
dc.identifier.epage71en_US
dc.identifier.isiWOS:000303420000006-
dc.publisher.placeUnited States-
dc.identifier.scopusauthoridLi, M=26661782700en_US
dc.identifier.scopusauthoridXu, A=7202655409en_US
dc.identifier.scopusauthoridLam, KSL=8082870600en_US
dc.identifier.scopusauthoridCheung, BMY=7103294806en_US
dc.identifier.scopusauthoridTse, HF=7006070805en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats